- Home
- CAI vs TECH Comparison
CAI vs TECH Comparison
Compare CAI & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAI
- TECH
- Stock Information
- Founded
- CAI 2008
- TECH 1976
- Country
- CAI United States
- TECH United States
- Employees
- CAI N/A
- TECH N/A
- Industry
- CAI Medical Specialities
- TECH Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CAI Health Care
- TECH Health Care
- Exchange
- CAI Nasdaq
- TECH Nasdaq
- Market Cap
- CAI 8.3B
- TECH 7.8B
- IPO Year
- CAI 2025
- TECH 1989
- Fundamental
- Price
- CAI $30.33
- TECH $50.01
- Analyst Decision
- CAI Strong Buy
- TECH Buy
- Analyst Count
- CAI 6
- TECH 12
- Target Price
- CAI $32.33
- TECH $69.82
- AVG Volume (30 Days)
- CAI 552.8K
- TECH 2.5M
- Earning Date
- CAI 01-01-0001
- TECH 08-06-2025
- Dividend Yield
- CAI N/A
- TECH 0.63%
- EPS Growth
- CAI N/A
- TECH N/A
- EPS
- CAI N/A
- TECH 0.46
- Revenue
- CAI $452,498,000.00
- TECH $1,219,635,000.00
- Revenue This Year
- CAI $44.16
- TECH $7.33
- Revenue Next Year
- CAI $62.71
- TECH $9.32
- P/E Ratio
- CAI N/A
- TECH $109.61
- Revenue Growth
- CAI 34.67
- TECH 5.23
- 52 Week Low
- CAI $25.40
- TECH $46.01
- 52 Week High
- CAI $33.41
- TECH $80.95
- Technical
- Relative Strength Index (RSI)
- CAI N/A
- TECH 39.44
- Support Level
- CAI N/A
- TECH $47.66
- Resistance Level
- CAI N/A
- TECH $55.28
- Average True Range (ATR)
- CAI 0.00
- TECH 2.25
- MACD
- CAI 0.00
- TECH -0.86
- Stochastic Oscillator
- CAI 0.00
- TECH 20.24
About CAI Caris Life Sciences Inc. Common Stock
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
About TECH Bio-Techne Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.